Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Johnson Financial Group Inc.

Johnson Financial Group Inc. increased its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 246.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 15,866 shares of the biopharmaceutical company's stock after buying an additional 11,291 shares during the quarter. Johnson Financial Group Inc.'s holdings in Bristol-Myers Squibb were worth $946,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Transce3nd LLC acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $28,000. Fairway Wealth LLC acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $28,000. Comprehensive Financial Planning Inc. PA acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $34,000. Westend Capital Management LLC acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $38,000. Finally, Tacita Capital Inc acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $39,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insiders Place Their Bets

In other news, EVP Samit Hirawat bought 4,250 shares of the firm's stock in a transaction on Friday, April 25th. The stock was purchased at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 0.09% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on BMY. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Argus raised Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Citigroup boosted their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $55.00 target price (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, Bristol-Myers Squibb presently has a consensus rating of "Hold" and a consensus price target of $58.00.

Bristol-Myers Squibb Trading Up 2.0 %

Shares of BMY traded up $0.99 during mid-day trading on Wednesday, hitting $50.21. The company had a trading volume of 15,943,801 shares, compared to its average volume of 12,957,945. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.33. The business's 50-day simple moving average is $56.11 and its 200-day simple moving average is $56.45. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The stock has a market cap of $102.17 billion, a PE ratio of -11.36, a P/E/G ratio of 2.07 and a beta of 0.41.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The business's quarterly revenue was down 5.6% on a year-over-year basis. During the same quarter last year, the firm posted ($4.40) earnings per share. Sell-side analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 4.94%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is presently 92.88%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.